The molecular basis of smoking-related cancers have been studied by the scientists to help doctors treat patients by knowing what genes to target with drugs.

TOP INSIGHT
Genomic instability is the cause for developing cancer and regulation of genome stability is centered around environmental and lifestyle factors.
"This data suggests that increases in TP53 mutation in African-Americans may be responsible for the observed resistance to chemotherapy and a poorer prognosis overall." The trial at Wake Forest Baptist enrolled 431 cancer patients from March 2015 to May 2016. The majority of the patients had advanced tobacco-related cancers - lung, colorectal and bladder - and 13.5 percent were African-American.
Tumors from study participants were sequenced to identify mutations and genetic alterations associated with smoking and/or African-American ancestry. The proportion of smokers was similar among African-American and Caucasian participants. Scientists validated their findings through the Cancer Genome Atlas dataset that includes 2,821 cases with known smoking status.
Both the Wake Forest Baptist and Cancer Genome Atlas cohorts revealed a significantly increased mutation rate in the TP53 gene in the African-American groups studied. The researchers also found that a number of genes including those that repair DNA damage and remodel chromatin - mutated at higher frequencies in the African-American cancer patients.
Additionally, the Wake Forest Baptist team identified other genes that were highly mutated in current and former smokers, regardless of race.
Due to the relatively small number of participants in the Wake Forest Baptist study, the findings need further validation in a larger trial, Zhang said.
"These exciting findings uncover new genetic information related to smoking that may lead to the development of novel diagnostic and therapeutic options for patients," said the study's co-corresponding author, Boris Pasche, M.D., Ph.D., director of the Comprehensive Cancer Center at Wake Forest Baptist.
Source-Eurekalert
MEDINDIA




Email










